相关实验视频

Updated: Jul 30, 2026

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

分子子组在I期高度子宫内膜癌中复发的模式

Alicia León-Castillo¹, Nanda Horeweg², Elke E M Peters³

¹Antoni van Leeuwenhoek Hospital, Department of Pathology, P.O. Box 90203, 1006 BE Amsterdam, the Netherlands; Leiden University Medical Center, Department of Pathology, P.O. Box 9600, 2300 RC Leiden, the Netherlands.

Gynecologic oncology

|April 23, 2025

概括

高度子宫内膜癌 (EC) 的复发模式因分子子组而异. 波尔突变 (POLEmut) 和不匹配修复缺陷 (MMRd) EC的复发率较低,而p53-异常 (p53abn) 和无特异分子谱 (NSMP) EC经常远程复发.

科学领域:

妇科瘤学妇科瘤学
分子病理学分子病理学
癌症复发的可能

背景情况:

子宫内膜癌 (EC) 复发模式影响救援治疗和患者预后.
了解分子子组特异性复发对于风险分层和治疗规划至关重要.

研究的目的:

评估I阶段高度EC分子子组的复发率和模式.
为了比较没有辅助治疗的患者和通过淋巴切除术分期的患者的结局.

主要方法:

412个高度EC病例的分子概况分为POLE突变 (POLEmut),不匹配修复缺陷 (MMRd),p53-异常 (p53abn) 和没有特定分子概况 (NSMP) 的子组.
排除II-IV阶段或残留疾病的患者.
原始和保险学复发率的计算.

主要成果:

第I阶段高等级POLEmut和MMRdEC的5年复发率较低 (分别为7%和6%),即使没有辅助治疗.
第一个阶段的高级NSMP和p53abnEC呈现出高5年复发率 (分别为29%和35%).
在NSMP和p53abn EC中,复发主要是腹部或远部.

结论:

第一个阶段的高度EC复发通常是腹部或远部,不论分子子组.
在没有辅助治疗的情况下,POLEmut和MMRd EC亚组的预后是有利的,复发率最小,即使没有辅助治疗.
在NSMP和p53abn EC中高复发率需要对更有效的全身辅助治疗进行研究.

关键词:

辅助性治疗是一种辅助性治疗.这是子宫内膜癌的癌症.淋巴管切除术是指淋巴管切除术.分子风险因素分子风险因素复发情况复发情况

更多相关视频

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

Multiplexed Fluorescent Immunohistochemical Staining of Four Endometrial Immune Cell Types in Recurrent Miscarriage

Multiplexed Fluorescent Immunohistochemical Staining of Four Endometrial Immune Cell Types in Recurrent Miscarriage

Published on: August 4, 2021

相关概念视频

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

Metastasis

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...